STAT3 and colorectal carcinoma: Since both the Nampt inhibitor FK866 and the Stat3 inhibitor C188‐9 can inhibit the Stat3‐Gpx4 signaling axis, we hypothesized that the antitumor effect on CRC could be synergistically enhanced by combining FK866 with C188‐9.